Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Stock Information for Avai Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avai Bio Inc.

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
The Credibility Filter Wall Street Uses to Sort Biotech Winners
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
Annovis Publishes Historical Review of Buntanetap in The Scientist
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.